Skip to main content

Table 3 Description of patients from C3 and C4 cohorts at the 6-month visit after applying propensity score matching

From: Switching first-line targeted therapy after not reaching low disease activity within 6 months is superior to conservative approach: a propensity score-matched analysis from the ATTRA registry

  C3 (n = 75) C4 (n = 75) p value
Female, n (%)* 60 (80.0%) 61 (81.3%) 0.836
Age at diagnosis, years, median (IQR) 45.0 (36.0–53.0) 45.0 (37.0–53.0) 0.678
Age at start of 1st line, years, median (IQR)* 52.0 (45.0–61.0) 55.0 (44.0–61.0) 0.811
Disease duration, years, median (IQR)* 5.0 (2.4–12.7) 5.8 (3.0–13.1) 0.937
RF positive, n (%)* 60 (80.0%) 54 (72.0%) 0.251
Presence of comorbidities, n (%)* 54 (72.0%) 55 (73.3%) 0.855
Currently smoking, n (%)* 21 (28.0%) 21 (28.0%) 1.000
Number of previous csDMARDs, n (%)*
 0 2 (2.7%) 0 (0.0%) 0.230
 1 16 (21.3%) 15 (20.0%)
 2 20 (26.7%) 28 (37.3%)
 3 17 (22.7%) 20 (26.7%)
 4+ 20 (26.7%) 12 (16.0%)
Glucocorticoids in previous history, n (%)* 67 (89.3%) 66 (88.0%) 0.797
Concomitant csDMARDs, n (%)* 61 (81.3%) 63 (84.0%) 0.666
Concomitant GCs, n (%)* 56 (74.7%) 55 (73.3%) 0.852
DAS28-ESR (0–10), median (IQR) 5.0 (4.2–5.9) 5.0 (4.1–5.7) 0.717
TJC (28 joints), median (IQR)* 8.0 (4.0–12.0) 6.0 (3.0–11.0) 0.677
SJC (28 joints), median (IQR)* 4.0 (2.0–8.0) 4.0 (2.0–7.0) 0.973
ESR (mm/h), median (IQR)* 27.0 (15.0–37.0) 25.0 (12.0–41.0) 0.844
CRP (mg/l), median (IQR)* 15.0 (8.0–22.2) 8.4 (3.5–25.7) 0.090
SDAI (0–86), median (IQR) 25.5 (15.6–34.9) 22.7 (16.1–30.9) 0.531
PTGA (0–100), median (IQR)* 60.0 (40.0–71.0) 50.0 (40.0–71.0) 0.519
MDGA (0–100), median (IQR) 55.0 (35.0–70.0) 45.0 (30.0–60.0) 0.059
HAQ-DI (0–3), median (IQR)* 1.5 (1.1–1.9) 1.5 (1.1–1.9) 0.877
EQ-5D (− 0.59–1), median (IQR)a 0.2 (0.1–0.7) 0.6 (0.1–0.7) 0.290
  1. These parameters were included in the propensity score model
  2. IQR interquartile range, RF rheumatoid factor, csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs, GCs glucocorticoids, DAS28-ESR 28-joint disease activity score with ESR, TJC tender joint count, SJC swollen joint count, ESR erythrocyte sedimentation rate, CRP C-reactive protein, SDAI Simplified Disease Activity Index, PTGA patient general assessment of disease activity, MDGA physician general assessment of disease activity, HAQ-DI Health Assessment Questionnaire, EQ-5D EuroQol 5 Dimension for measuring the quality of life
  3. an = 74 (C3), n = 75 (C4)